Athira Pharma, Inc. (NASDAQ:ATHA) Short Interest Update

Athira Pharma, Inc. (NASDAQ:ATHA) saw a large drop in short interest in the month of January. As of January 15th, there was short interest totalling 1,170,000 shares, a drop of 17.6% from the December 31st total of 1,420,000 shares. Approximately 3.3% of the shares of the stock are sold short. Based on an average trading volume of 4,600,000 shares, the short-interest ratio is currently 0.3 days.

Institutional Trading of Athira Pharma

Several large investors have recently modified their holdings of the business. XTX Topco Ltd purchased a new stake in Athira Pharma in the 2nd quarter valued at approximately $60,000. Invst LLC purchased a new stake in shares of Athira Pharma in the second quarter valued at $68,000. American Century Companies Inc. boosted its stake in shares of Athira Pharma by 9.4% during the second quarter. American Century Companies Inc. now owns 38,940 shares of the company’s stock valued at $103,000 after acquiring an additional 3,333 shares during the last quarter. Renaissance Technologies LLC increased its position in Athira Pharma by 3.5% during the 2nd quarter. Renaissance Technologies LLC now owns 271,488 shares of the company’s stock worth $719,000 after purchasing an additional 9,164 shares in the last quarter. Finally, Bristlecone Advisors LLC raised its stake in Athira Pharma by 295.6% in the 3rd quarter. Bristlecone Advisors LLC now owns 337,506 shares of the company’s stock valued at $151,000 after purchasing an additional 252,200 shares during the last quarter. 57.12% of the stock is currently owned by institutional investors and hedge funds.

Athira Pharma Stock Performance

ATHA stock traded up $0.01 during midday trading on Thursday, hitting $0.53. 463,920 shares of the stock were exchanged, compared to its average volume of 211,201. The stock has a market cap of $20.65 million, a price-to-earnings ratio of -0.19 and a beta of 2.99. Athira Pharma has a fifty-two week low of $0.41 and a fifty-two week high of $4.30. The stock’s 50-day moving average price is $0.58 and its 200-day moving average price is $1.23.

Athira Pharma (NASDAQ:ATHA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.05. Research analysts anticipate that Athira Pharma will post -2.35 EPS for the current year.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.